BioLife Solutions, Inc., a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, has announced that Mustang Bio, Inc., has adopted BioLife’s CryoStor cell freeze media and evo cold chain system for use in current and upcoming clinical trials.
BioLife Solutions, founded in 1987, headquartered in the Greater Seattle Area, west coast USA, is the leading developer, manufacturer and supplier of proprietary biopreservation media for cells and tissues. HypoThermosol® hypothermic storage and CryoStor® cryopreservation freeze media are highly valuable in the regenerative medicine, biobanking and drug discovery markets.
BioLife’s biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. The recently acquired ThawStar® family of automated cell thawing products and evo cold chain management system reduce therapeutic and economic risk for cell and gene therapy developers by reducing the potential of administering a non-viable dose.
A fortress biotech company, Mustang Bio, Inc., founded in 2015, based in Worcester, Massachusetts, is a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for XSCID.
After rigorous evaluations of various alternatives on the market, Mustang selected BioLife’s proprietary CryoStor and evo products to support best biopreservation practices, which focus on maximizing manufacturing yield and quality while reducing distribution-related risks, such as temperature excursions and in-transit shipping damage. The evo cold chain system was added to BioLife’s product portfolio via the recently announced acquisition of SAVSU Technologies.
“We appreciate the opportunity to support Mustang’s clinical programs. Our growing product portfolio is comprised of tools that can reduce the risk of delivering a non-viable dose, and the resulting therapeutic failure and economic loss for cell and gene therapy developers.” – Mike Rice, BioLife’s CEO
Sources
